CareRx (FRA:29C1) GF Value Rank: 5 (As of Aug. 13, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:29C1 CareRx Corp FRA:29C1
68 GF Score
Price €2.06
GF Value €1.37
! 3 Warning Signs
View Full Analysis

What is CareRx GF Value Rank?

CareRx FRA:29C1 68 GF Value Rank is 5 as of Aug. 13, 2026, which is at its 10-year median of 5.00. GuruFocus rates FRA:29C1 with a GF Score™ of 68/100 and a GF Value™ of €1.37. The stock has 3 warning signs investors should review.

CareRx has the GF Value Rank of 5.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


FRA:29C1 vs HCA, THC, DVA: GF Value Rank Comparison

For the Medical Care Facilities subindustry, CareRx's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CareRx GF Value Rank vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, CareRx's GF Value Rank distribution charts can be found below:

* The bar in red indicates where CareRx's GF Value Rank falls into.


FRA:29C1
68GF Score
CareRx Corp FRA:29C1
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 5 mean?
CareRx (FRA:29C1) has a GF Value Rank of 5 as of Aug. 13, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on CareRx and its competitors. This is near median its historical median of 5.00. Over the past decade, CareRx's GF Value Rank has ranged from 1.00 to 10.00.
Is CareRx's GF Value Rank too high?
CareRx's current GF Value Rank of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, CareRx has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does CareRx's GF Value Rank compare to HCA and THC?
CareRx's GF Value Rank of 5 can be compared against companies in the Healthcare Providers & Services industry. Historically, CareRx's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Healthcare Providers & Services company?
A good GF Value Rank depends on the Healthcare Providers & Services industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on CareRx and its competitors. CareRx's current GF Value Rank is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareRx stock overvalued right now?
CareRx (FRA:29C1) has a current GF Value Rank of 5. The stock's GF Value™ is €1.37, compared to a current price of €2.06 — trading 50.4% above its estimated fair value. The current GF Value Rank is 5, which is near median its 10-year median of 5.00. CareRx's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For CareRx (FRA:29C1), the current GF Value Rank is 5 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CareRx (FRA:29C1) Overvalued in 2026?

Based on GuruFocus' analysis, CareRx stock appears to be overvalued. The current stock price of €2.06 is trading 50.4% above its estimated GF Value™ of €1.37.

Key valuation signals for FRA:29C1:

  • GF Value Rank: 5 (near median its 10-year median of 5.00)
  • GF Value™: €1.37 vs. price of €2.06 (50.4% above fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the FRA:29C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CareRx Business Description

Other Exchanges CHHHF:USACRRX:Canada
Address 320 Bay Street, Suite 1200, Toronto, ON, CAN, M5H 4A6
CareRx Corp is a provider of specialty pharmacy services to seniors. The company is a national organization with a large network of pharmacy fulfilment centers strategically located across the country. This allows it to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. It takes an active role in working with its home operator partners to promote resident health, staff education and medication system quality and efficiency. The Company has one reportable segment which consists of the Company-owned and operated institutional pharmacy business. Geographically it derives revenue from the sales of goods and capitated service fees in Ontario and Western Canada.
68GF Score

Get the complete analysis for FRA:29C1

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.06
Price
€1.37
GF Value